A carregar...
Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
Two new targeted agents have been approved for pediatric and adult patients with advanced or metastatic solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation. Larotrectinib and entrectinib are the second and third agents to be approved as...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press LLC
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7863124/ https://ncbi.nlm.nih.gov/pubmed/33604102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.4.9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|